22(R)-hydroxycholesterol and pioglitazone synergistically decrease cholesterol ester via the PPARγ-LXRα-ABCA1 pathway...

Area of Science:

• Biochemistry
• Cell Biology
• Metabolic Diseases

Background:

• Cholesterosis involves excessive lipid droplet accumulation in gallbladder epithelial cells (GBECs).
• Intracellular cholesterol homeostasis is crucial for gallbladder function.
• Peroxisome proliferator-activated receptor gamma (PPARγ) and liver X receptor α (LXRα) activation are linked to cholesterol efflux.

Purpose of the Study:

• To investigate the combined effect of 22(R)-hydroxycholesterol and pioglitazone on cholesterosis in GBECs.
• To elucidate the underlying molecular mechanisms involving the PPARγ-LXRα-ABCA1 pathway.

Main Methods:

• GBECs were treated with pioglitazone and/or 22(R)-hydroxycholesterol.
• Western blot analysis was used to assess protein expression (ABCA1, PPARγ, LXRα).
• Cholesterol efflux to apoA-I and lipid levels (Oil Red O staining) were measured.

Main Results:

• 22(R)-hydroxycholesterol upregulated LXRα and increased ABCA1 expression by 56%.
• The combination of 22(R)-hydroxycholesterol and pioglitazone led to a 3.64-fold increase in ABCA1 expression and high cholesterol efflux.
• Oil Red O staining revealed a significant reduction in lipid droplets in treated GBECs.

Conclusions:

• The combination therapy activates the PPARγ-LXRα-ABCA1 pathway, promoting cholesterol efflux.
• This synergistic approach effectively reduces lipid deposition in cholesterosis GBECs.
• 22(R)-hydroxycholesterol and pioglitazone show promise for treating gallbladder cholesterosis.